Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00688246 · ClinicalTrials.gov registry record
Bone Mineral Density in Postmenopausal Women at Increased Risk of Breast Cancer And Who Are Receiving Exemestane on MAP3
A clinical trial, sponsored by NCIC Clinical Trials Group.
- Completed
- Registry status
- 238
- Enrollment target
NCT00688246 is a clinical trial that has completed, run by NCIC Clinical Trials Group. The registered enrollment target is 238 participants.
The verdict
NCT00688246 has completed, sponsored by NCIC Clinical Trials Group.
- COMPLETED
- Registry status
- 238 participants
- Enrollment target
Study Summary
RATIONALE: Learning about the effect of exemestane on bone mineral density in postmenopausal women at increased risk of breast cancer may help plan treatment, decrease the risk of broken bones, and help patients live more comfortably. PURPOSE: This research study is measuring bone mineral density in postmenopausal women at increased risk of developing breast cancer who are receiving exemestane on clinical trial CAN-NCIC-MAP3.
Interventions
- OTHER biologic sample preservation procedure
- PROCEDURE dual x-ray absorptometry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 238 participants |
| Start Date | 2008-07-10 |
| Est. Completion | 2013-01-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00688246
The ClinicalTrials.gov registry entry for NCT00688246 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 238 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NCIC Clinical Trials Group, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which biologic sample preservation procedure is the first listed.
NCT00688246 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00688246 about?
NCT00688246 is a clinical study titled "Bone Mineral Density in Postmenopausal Women at Increased Risk of Breast Cancer And Who Are Receiving Exemestane on MAP3". RATIONALE: Learning about the effect of exemestane on bone mineral density in postmenopausal women at increased risk of breast cancer may help plan treatment, decrease the risk of broken bones, and help patients live more comfortably. PURPOSE: This research study is measuring bone mineral density i...
What is the current status of trial NCT00688246?
This trial is currently completed. The enrollment target is 238 participants. The study started on 2008-07-10. Estimated completion is 2013-01-10.
What interventions are being tested in trial NCT00688246?
The interventions under investigation include: biologic sample preservation procedure (OTHER), dual x-ray absorptometry (PROCEDURE).
Who is sponsoring clinical trial NCT00688246?
This trial is sponsored by NCIC Clinical Trials Group, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.